MedPath

Digital Home Ovulation Test One Cycle at Home Study

Completed
Conditions
Pregnancy
Fertility
Registration Number
NCT04667845
Lead Sponsor
SPD Development Company Limited
Brief Summary

This study will assess the usability of a Digital Home Ovulation Test when used at home by lay-users seeking to conceive.

Detailed Description

This study will assess the ease of use of a Digital Home Ovulation Test when used by lay-users for one cycle in their home environment. The home ovulation test to be used in the study is a digital home ovulation test used to detect luteinising hormone (LH) and Estrone-3-Glucuronide (E3G) in urine to identify when ovulation is imminent.

A sample size of 120 volunteers (minimum) will provide adequate information for assessing the usability of the home ovulation test. Usability of the test will be assessed through a questionnaire completed at the end of the study.

This observational study will be conducted remotely and volunteers representative of the intended user (lay-users) will be recruited.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
125
Inclusion Criteria
  • Female
  • Aged 18 to 45 years
  • Seeking to conceive
  • Willing to give informed consent and comply with the investigational procedures
Exclusion Criteria
  • Taking medication, or has known condition which means they should not get pregnant.

  • Currently pregnant or breastfeeding

  • Used the digital ovulation test within the last six months

  • Currently or previously employed by Swiss Precision Diagnostics (SPD), Abbott, Alere, Unipath, P&G or affiliates

  • Has an immediate* relative currently or previously (within past 5 years) employed by SPD, Abbott, Alere, Unipath or P&G, or affiliates

    *Immediate relatives are defined as parents, children, siblings or partner/spouse

  • Is a qualified or trainee healthcare professional (HCP)

  • Has professional experience of using dipstick type tests or lateral flow devices

  • Using any treatment which may affect the menstrual cycle (e.g. contraceptive pill)

  • Using infertility medications or hormone replacement medications containing Luteinising Hormone (LH) or Human Chorionic Gonadotrophin (hCG) (e.g. Pregnyl®)

  • Using or undergoing any other medical treatment for fertility such as ovulation drugs, artificial insemination and assisted fertility such as In vitro fertilization (IVF) or Intracytoplasmic sperm injection (ICSI)

  • Peri-or post-menopausal, e.g. experiencing symptoms: irregular menstrual periods, hot flushes, night sweats, sleep disturbances and/or moods swings

  • Has been diagnosed with polycystic ovarian syndrome (PCOS)

  • Has PCOS symptoms e.g. very irregular cycles, hirsutism

  • Has abnormal liver or kidney function

  • Is taking antibiotics containing tetracycline

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Device usabilityOne menstrual cycle, average 28 days

The usability of the digital home ovulation test when used at home by volunteers seeking to conceive scored on a 7 point Likert scale where 1 is the lowest (most negative) score and 7 is the highest (most positive) score.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

SPD Development Company Ltd

🇬🇧

Bedford, Bedfordshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath